Benefit of early conversion from CNI-based to everolimus-based immunosuppression in heart transplantation.
Gude
Einar
E
Department of Cardiology, Oslo University Hospital, Oslo, Norway. einar.gude@rikshospitalet.no
Gullestad
Lars
L
Arora
Satish
S
Simonsen
Svein
S
Hoel
Ina
I
Hartmann
Anders
A
Holdaas
Hallvard
H
Fiane
Arnt E
AE
Geiran
Odd R
OR
Andreassen
Arne K
AK
D065095:Calcineurin Inhibitors; D003404:Creatinine / Q000097:blood; D016572:Cyclosporine / Q000009:adverse effects / Q000627:therapeutic use*; D000068338:Everolimus; D005260:Female; D005500:Follow-Up Studies; D005919:Glomerular Filtration Rate; D006084:Graft Rejection / Q000453:epidemiology / Q000628:therapy; D016027:Heart Transplantation; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D015994:Incidence; D007668:Kidney / Q000187:drug effects / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D011184:Postoperative Period; D020127:Recovery of Function; D019233:Retreatment; D020123:Sirolimus / Q000031:analogs & derivatives* / Q000627:therapeutic use; D017741:Survivors; D013997:Time Factors
D065095:Calcineurin Inhibitors; D007166:Immunosuppressive Agents; D016572:Cyclosporine; D000068338:Everolimus; D003404:Creatinine; D020123:Sirolimus